Scroll down for text









With the nation's economy in recession, it probably comes as little surprise that many companies are scaling back executive bonuses for year-2001 performance. However, if health care bonus packages are any indication, then the industry itself would seem to be more immune to the effects of the economy than most other businesses.

A survey of 350 employers by Towers Perrin, the management and human resources consulting company, found that half intend to reduce bonuses 25 percent or more compared with levels paid last year — or pay none at all. "Many companies feel that performance does not justify the bonuses paid in the last several years," says Allen Jackson, principal in charge of data and technology for Towers Perrin's Executive Compensation practice.

Things aren't quite so drastic in health care, where less than a third say they'll cut bonus packages by at least one fourth, and in fact, none plan to scotch bonuses altogether. Health care organizations make up just over 8 percent of the Towers Perrin sample.

The health care segment is heavily weighted toward life and health insurers, while not-for-profit hospitals and health care organizations round out the group. "Anecdotally, we're not seeing drastic reductions in bonus programs among not-for-profit organizations," says Kathy Hastings, principal and health care industry consultant, "particularly because they're not dependent on stock price."

A sizeable share of companies that Towers Perrin surveyed also are reining in salary increases this year. Technology, entertainment, and financial-service businesses are among the hardest hit, while health care and pharmaceuticals report little or no change in salary increases, compared to 2001.

SOURCE: TOWERS PERRIN, NEW YORK, 2002

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.